Particle and Heavy Ion Transport Code System-Based Microdosimetry for the Development of Boron Agents for Boron Neutron Capture Therapy

Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells at the cellular level using the boron neutron capture reaction (BNCR) (10B(n.alpha)7Li). The amount of boron B-10 delivers in boronophenylalanine (BPA)-BNCT to achieve anti-tumor effects is approximate to 15-40 ppm. The same is true for all boron drugs; however, whether the same amount of B-10 is required for other boron drugs with different accumulation characteristics has not been intensively investigated. Therefore, herein, a virtual cell model with intracellular organelles is prepared, and the BPA equivalent dose concentration to the cell nucleus is analyzed using particle and heavy ion transport code system-based microdosimetry. Additionally, the intranuclear minimal region (IMR) is set as a reference for the concept of the intranuclear domain in the microdosimetric kinetic model, and the BPA equivalent dose concentration to the IMR is estimated. The required boron delivery dose greatly varies depending on the dose assessment based on the accumulation characteristics of boron agents in intracellular organelles. Evaluation of the BNCR effect according to the accumulation characteristics without being influenced by the specified value of 15-40 ppm is recommended.

Automated summary

Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells using the boron neutron capture reaction. The delivery dose of boron B-10 for anti-tumor effects in boron drugs is approximately 15-40 ppm, but its requirement for different boron drugs with different accumulation characteristics has not been extensively investigated.